Inmune Bio, Inc. 8-K

What Happened
On February 19, 2026, Inmune Bio, Inc. (INMB) announced via press release that it will host a webinar on CORDStrom, its investigational therapy for recessive dystrophic epidermolysis bullosa (RDEB). The webinar is scheduled for February 26, 2026 at 1:00 p.m. ET. The company filed the announcement on Form 8-K (Item 8.01) and attached the press release as Exhibit 99.1.

Key Details

• Press release announcing the webinar dated February 19, 2026.
• Webinar date and time: February 26, 2026 at 1:00 p.m. ET.
• Topic: CORDStrom treatment program for recessive dystrophic epidermolysis bullosa (RDEB).
• The announcement was reported on Form 8-K and the press release is included as Exhibit 99.1.

Why It Matters
This is an investor- and stakeholder-facing update about Inmune Bio’s clinical program for RDEB. Webinars can provide more detail on development plans, clinical data or timelines; any material clinical or regulatory developments would typically be followed up with formal SEC disclosures. Retail investors may want to monitor the webinar and subsequent company filings for substantive program updates that could affect the company’s prospects.